Chris Gordon
Managing Director @ Bain Capital Private Equity
Boston, United States
Chris Gordon is a private equity investor at Bain Capital Private Equity in Boston focused on Biotechnology and Pharmaceutical. Chris Gordon
- Total investments:
- 3
- Last investment:
- Lead investor:
- 67%
Last updated:
For AI agents: llms.txt
Industries Chris Gordon invests in
Stages Chris Gordon invests in
Countries Chris Gordon invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 2 (67%)
- Pharmaceutical 2 (67%)
- Health Care 1 (33%)
- Therapeutics 1 (33%)
- Medical Device 1 (33%)
Stage
- Private Equity 2 (67%)
- Series B 1 (33%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Kailera Therapeutics is a clinical-stage biotechnology company that provides revolutionary therapies for treating obesity and related diseases. | $600M / Series B / Oct 14, 2025 | ||
| Kestra Medical Technologies is a wearable medical device and digital healthcare company that protects patients with diagnostic and therapeutic technologies that are intuitive, and mobile. They provide intuitive medical technologies to protect and support at-risk patients. | $196M / Private Equity / Jul 24, 2024 | ||
| Cerevel Therapeutics is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases. The company is tackling neuroscience diseases with a differentiated approach that combines expertise in neurocircuitry with a focus on receptor selectivity. Cerevel Therapeutics has a diversified pipeline comprising five clinical-stageinvestigational therapies and several preclinical compounds with the potential to treat a range of neuroscience diseases, including schizophrenia, epilepsy, Parkinson’s disease and substance use disorder. | $350M / Private Equity / Oct 26, 2018 |
Co-Investors
Bain Capital Private Equity is a private equity firm that focuses on a value-added investment approach. Their globally integrated teams leverage deep vertical expertise and partner with management teams around the world to accelerate growth.
Bain Capital Private Equity Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Adam Koppel
Managing Director
|
|||
|
Chris Gordon
Managing Director
|
|||
John Connaughton
Global Head
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Chris Gordon invest in?
Chris Gordon invests primarily in Biotechnology, Pharmaceutical and Health Care startups, most often at Private Equity and Series B stage. Most of the 3 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Chris Gordon?
Public channels for Chris Gordon include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Chris Gordon last invest?
The most recent investment recorded for Chris Gordon closed in Oct 2025. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
